Mira Pharmaceuticals (MIRA) EPS (Weighted Average and Diluted) (2022 - 2025)

Mira Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting $0.1 for Q4 2025.

• EPS (Weighted Average and Diluted) for Q4 2025 came in at $0.1, up 166.67% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.28 (down 132.73% YoY), and the FY2025 annual result was -$1.35, down 164.71% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.1 for Q4 2025 at Mira Pharmaceuticals, up from -$1.18 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.1 in Q4 2025 to a low of -$1.18 in Q3 2025.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.14 (2022), against an average of -$0.2.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 1433.33% in 2023 and surged 166.67% in 2025, its largest moves.
• Mira Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.03 in 2022, then tumbled by 1433.33% to -$0.4 in 2023, then surged by 62.5% to -$0.15 in 2024, then soared by 166.67% to $0.1 in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.1 (Q4 2025), -$1.18 (Q3 2025), and -$0.09 (Q2 2025), per Business Quant data.